Description
Vivimed Labs Limited (VIVIMEDLAB) will be transferred from BE series to EQ series effective December 26, 2025.
Summary
NSE has announced the transfer of trading in securities of Vivimed Labs Limited (Symbol: VIVIMEDLAB) from the BE (Book Entry) series to the EQ (Equity) series, effective December 26, 2025. This transfer is pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
Key Points
- Company: Vivimed Labs Limited
- Symbol: VIVIMEDLAB
- Transfer: From BE series to EQ series
- Effective Date: December 26, 2025
- Circular Reference: NSE/CML/71870, Circular No. 2469/2025
- Regulatory Framework: SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
Regulatory Changes
The transfer from BE series to EQ series represents a change in the trading category for Vivimed Labs Limited. The BE series typically includes securities under enhanced surveillance or those not meeting certain compliance requirements, while the EQ series represents normal equity trading. This transfer indicates that the company has met the necessary criteria to move to standard equity trading.
Compliance Requirements
- Exchange members must note the series change for Vivimed Labs Limited
- Trading systems should be updated to reflect the new EQ series classification
- All trading in VIVIMEDLAB must be conducted in EQ series from December 26, 2025 onwards
Important Dates
- Circular Date: December 18, 2025
- Effective Date: December 26, 2025
Impact Assessment
The transfer from BE to EQ series is a positive development for Vivimed Labs Limited, indicating improved compliance and corporate governance standards. This change may:
- Improve liquidity as EQ series typically attracts more institutional investors
- Reduce trading restrictions associated with BE series
- Enhance investor confidence in the security
- Potentially reduce margin requirements for traders
- Allow broader participation in the stock as surveillance measures are relaxed
Impact Justification
Transfer from BE to EQ series indicates improved compliance status for Vivimed Labs, affecting trading conditions and investor access